Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Prince Harry embarks on a new courtroom battle against British tabloids in his case against Rupert Murdoch’s News Group ...

Molecular subunits link to produce polymer chains that can connect through their backbones and cross-linked molecules to form ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Using fermentation, University of Alberta researchers have come up with a way to produce higher amounts of a healthy fatty ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies looking to enter new markets. Let's delve into how companies can take a ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against the other CRISPR stocks.

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

51% of the business is held by the top 14 shareholders Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock Every investor in CRISPR ...